πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

6,931 results for β€œThe” Clear

  1. Icotinib

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  2. Icotinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  4. IkT-001Pro

    Inhibikase Therapeutics

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule terminated

    1 trial

  5. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  6. Iloperidone crystalline formulation

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  7. Imatinib

    The First People's Hospital of Lianyungang

    Progression-free Survival

    phase 2 small molecule active

    1 trial

  8. Imatinib Mesylate

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  9. Immunological Agent

    The First People's Hospital of Lianyungang

    Lung Cancer Metastatic

    phase 2 small molecule active

    1 trial

  10. Immunotherapy combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Impedance Threshold Device

    United Therapeutics Europe Ltd

    Hypotension

    phase 2 other completed

    1 trial

  12. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 2 mab completed

    1 trial

  13. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Palmoplantar Pustulosis

    phase 2 mab completed

    1 trial

  14. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  15. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Ichthyosis

    phase 2 small molecule terminated

    1 trial

  16. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acneiform Eruptions

    phase 2 mab terminated

    1 trial

  17. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

  18. Indapamide

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  19. Indibulin

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  20. Induction Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

    phase 2 small molecule active

    1 trial

  21. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  22. Induction therapy of GP(Pomalidomide+ObinutuzumabοΌ‰

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial

  23. Inetetamab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  24. Infigratinib

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources